SUBSCRIBE
SUBSCRIBE

Multiple sclerosis

Pictured: Sanofi Distribution Center
Drug Development
Sanofi Gets Phase II MS Win, Eyes $5B in Peak Annual Sales for Pipeline
The French drugmaker Thursday touted trial results in The New England Journal of Medicine showing frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis.
February 15, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Load More
PRESS RELEASES
Press Releases
Data of InnoCare’s Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum
February 26, 2025
 · 
3 min read
Press Releases
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice
February 26, 2025
 · 
5 min read
Press Releases
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
February 19, 2025
 · 
5 min read
Press Releases
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 18, 2025
 · 
14 min read
Press Releases
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
 · 
6 min read
Press Releases
AB Science today provides an update on its masitinib platform
January 30, 2025
 · 
4 min read
Press Releases
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
January 23, 2025
 · 
6 min read
Press Releases
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
January 22, 2025
 · 
9 min read
Press Releases
Pheno Therapeutics Granted Clinical Trial Authorisation for Lead Multiple Sclerosis Therapeutic Candidate PTD802
January 14, 2025
 · 
2 min read
Press Releases
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
January 14, 2025
 · 
12 min read
Press Releases
Cycle Pharma Acquires Banner Life Sciences, LLC
January 13, 2025
 · 
17 min read
Press Releases
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
January 9, 2025
 · 
5 min read
Press Releases
Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis
December 24, 2024
 · 
2 min read
Press Releases
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
December 13, 2024
 · 
8 min read
Press Releases
Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with ‘Neurophet AQUA’
November 25, 2024
 · 
3 min read
Press Releases
LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases
November 21, 2024
 · 
4 min read
Press Releases
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
November 19, 2024
 · 
6 min read
Press Releases
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
November 5, 2024
 · 
20 min read
Press Releases
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
October 30, 2024
 · 
6 min read
Press Releases
Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
October 28, 2024
 · 
6 min read
Load More